The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
However, the published data on DAC is better than the public consensus gives it credit for: sustained GHRH signaling without abolishing pulses, 7.5x overnight GH trough, >150% IGF-1 increase after two weekly doses at 30 µg/kg.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
CJC-1295 with DAC: the long acting version. One injection per week, stays active for 6–8 days. This is what was used in the actual clinical trials. Raises GH 2–10x and IGF-1 1.5–3x from a single dose. Preserves GH pulsatility even under continuous stimulation.
The purist in us says stick with DAC; that's where the published data lives.
Compare CJC-1295 DAC: single injection, IGF-1 up 1.5–3x for up to 11 days, above baseline for up to 28 days.
One peptide, one shot per week.